Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

10-Year checkup: are silimed breast implants safe and satisfying?

NCT ID NCT03356132

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 632 women who received Silimed breast implants (textured or polyurethane-coated) for augmentation. Researchers will track side effects and satisfaction over 10 years to understand the implants' safety and performance. The goal is to gather real-world data, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 632 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2018

Expected to finish

Dec 2036

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women aged 18 years old or older who have undergone breast augmentation using Silimed® silicone gel-filled breast implants with textured surface or Silimed® silicone gel-filled breast implants with polyurethane foam coated surface.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * provide written informed consent. * female at birth * be 18 years of age or older * have received breast implant(s) for indication of primary or secondary augmentation until 21 days before (including the visit window) * having received a breast implant with a textured surface or a breast implant with a surface coated with Silimed® polyurethane foam * ability to comply with the protocol throughout the follow-up period. Exclusion Criteria: * mammary reconstruction in at least one breast or augmentation after previous reconstruction, * pregnancy informed or breastfeeding at the inclusion moment, * advanced fibrocystic disease at the time of implantation, * neoplasia of any type not yet treated or being treated at the time of implantation, infection in activity not yet treated or being treated at any site at the time of implantation, * reporting or recording of adverse reactions or intolerance to polyurethane or silicone prior to implantation, * immune diseases affecting active connective tissue or (eg, lupus erythematosus, discoid lupus, scleroderma, etc.) at the time of implantation, * signs of inflammation of the breast or implant site at the time of implantation, * Increased risk of immediate postoperative complications due to use of illicit drugs or medications, * Increased risk of immediate post-surgical complications caused by illicit drug use or medication use, * have participated in another clinical study up to 6 months prior to the placement of the implant, * any other condition which, based on the opinion of the investigator or designee, may prevent the provision of informed consent, renders participation in the study is unsafe, compromises adherence to the protocol, complicates the interpretation of data from the study outcome, or otherwise interferes with the achievement of study objectives.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast implant complications are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Personal Satisfaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Perfektua Serviços Médicos Ltda

    RECRUITING

    Niterói, Rio de Janeiro, 24230-052, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.